Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, X, R.sub.2 and R.sub.3 are as defined herein.
Highly effective asymmetrichydrogenation of β-ketophosphonates in the presence of Ru–(S)-SunPhos as catalyst was realized; good to excellent enantioselectivities (up to 99.9% ee) and excellent diastereoselectivities (96:4) were obtained.
The highly chemo- and enantioselective hydrogenation of (E)-2-substituted-4-oxo-2-alkenoic acids was established for the first time using the Rh/JosiPhos complex, affording a series of chiral α-substituted-γ-keto acids with excellent results (up to 99% yield and >99% ee) and high efficiency (up to 3000 TON). In addition, the importance of this methodology was further demonstrated by a concise and gram-scale
Provided herein are compounds of formula (I):
as well as pharmaceutically acceptable salts and esters thereof, which are useful as pharmaceutical compositions for the treatment of metabolic diseases and disorders.
Iridium‐catalyzed asymmetric hydrogenation of β‐ketophosphonates with chiral ferrocenyl P,N,N‐ligands
作者:Yin‐Feng Ma、Chuan‐Jin Hou、De‐Quan Wei、Xinwei He、Ting‐Ting Chu、Xiu‐shuai Chen、Xiang‐Ping Hu
DOI:10.1002/aoc.6283
日期:2021.8
The asymmetrichydrogenation of β-ketophosphonates with chiral Ir/P,N,N-ligands catalyst has been developed. A series of β-ketophosphonates were hydrogenated, and the corresponding β-hydroxyphosphonates were obtained in high yields with good or excellent enantioselectivities under mild condition.